التفاصيل البيبلوغرافية
| العنوان: |
Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. |
| المؤلفون: |
Spigoni, Valentina, Aldigeri, Raffaella, Antonini, Monica, Micheli, Maria Maddalena, Fantuzzi, Federica, Fratter, Andrea, Pellizzato, Marzia, Derlindati, Eleonora, Zavaroni, Ivana, Bonadonna, Riccardo R.C., Dei Cas, Alessandra |
| المصدر: |
International journal of molecular sciences, 18 (7 |
| سنة النشر: |
2017 |
| المجموعة: |
DI-fusion : dépôt institutionnel de l'Université libre de Bruxelles (ULB) |
| مصطلحات موضوعية: |
Sciences bio-médicales et agricoles, Adult, Aged, Berberine -- therapeutic use, Biological Products -- therapeutic use, Chitosan -- therapeutic use, Cholesterol -- blood, Drug Compounding, Dyslipidemias -- blood -- drug therapy, Female, Humans, Male, Middle Aged, Proprotein Convertase 9 -- metabolism, PCSK9, non-HDL cholesterol, nutraceuticals, randomized clinical trial |
| الوصف: |
Increased non high-density lipoprotein (HDL)/low-density lipoprotein (LDL) cholesterol levels are independent risk factors for cardiovascular (CV) mortality with no documented threshold. A new combination of nutraceuticals (berberine 200 mg, monacolin K 3 mg, chitosan 10 mg and coenzyme Q 10 mg) with additive lipid-lowering properties has become available. The aim of the study is to test the efficacy of the nutraceutical formulation (one daily) in lowering non-HDL cholesterol vs. placebo at 12 weeks in individuals with non-HDL-cholesterol levels ≥160 mg/dL. 39 subjects (age 52 ± 11 years; 54% females; body mass index 27 ± 4 kg/m²) were randomized (3:1) in a double blind phase II placebo-controlled study. At baseline, 4 and 12 weeks main clinical/biohumoral parameters, pro-inflammatory cytokines, (gut)-hormones, proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and endothelial progenitor cell (EPC) number were assessed. Baseline characteristics were comparable in the two groups. The intervention significantly decreased non-HDL cholesterol (-30 ± 20 mg/dL; p = 0.012), LDL cholesterol (-31 ± 18 mg/dL, p = 0.011) and apolipoprotein (Apo) B (-14 ± 12 mg/dL, p = 0.030) levels compared to the placebo. Pro-inflammatory, hormonal, PCSK9 and EPC levels remained stable throughout the study in both groups. The intervention was well tolerated. Three adverse events occurred: Epstein Barr virus infection, duodenitis and asymptomatic but significant increase in creatine phosphokinase (following intense physical exercise) which required hospitalization. The tested nutraceutical formulation may represent a possible therapeutic strategy in dyslipidemic individuals in primary prevention. ; info:eu-repo/semantics/published |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
1 full-text file(s): application/pdf |
| اللغة: |
English |
| العلاقة: |
uri/info:doi/10.3390/ijms18071498; uri/info:pii/ijms18071498; uri/info:pmid/28704936; uri/info:pmcid/PMC5535988; https://dipot.ulb.ac.be/dspace/bitstream/2013/317775/1/doi_301419.pdfTest; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/317775Test |
| الإتاحة: |
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/317775Test |
| رقم الانضمام: |
edsbas.87EE1D50 |
| قاعدة البيانات: |
BASE |
